Results 51 to 60 of about 12,593 (182)

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis

, 2022
Left ventricular (LV) remodeling after myocardial infarction (MI) is promoted by an intense fibrotic response, which could be targeted by the anti-fibrotic drug pirfenidone.
Galvez-Monton C., Burchielli S., Passino C., Iborra-Egea O., Aimo A., Emdin M., Martini N., Panichella G., Bayes-Genis A.   +8 more
core   +1 more source

Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects

Egyptian Journal of Chest Disease and Tuberculosis, 2020
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease, with a median survival of ∼2–5 years. The main target of treatment was to stabilize or reduce the rate of disease progression. Nintedanib and pirfenidone are new
Amal A.E.-A Sadon, Ahmed S Kenawy, Ashraf H Abdelsalam, Hosam M Attia   +3 more
doaj   +1 more source

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

Arthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken, Jeremy M. Weber, Megan L. Neely, Aparna C. Swaminathan, Scott M. Palmer, Erin M. Wilfong, Ann D. Chauffe, Elizabeth R. Volkmann   +7 more
wiley   +1 more source

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2019
Background Current clinical practice guidelines for idiopathic pulmonary fibrosis (IPF) conditionally recommend use of pirfenidone and nintedanib. However, an optimal treatment sequence has not been established, and the data of treatment sequence from ...
Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takuma Katano, Erina Tabata, Ryota Shintani, Shinko Sadoyama, Hideaki Yamakawa, Tsuneyuki Oda, Ryo Okuda, Hideya Kitamura, Tae Iwasawa, Tamiko Takemura, Takashi Ogura   +13 more
doaj   +1 more source

Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis

Scientific Reports, 2022
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology. Currently, pirfenidone and nintedanib are the only FDA-approved drugs for the treatment of IPF and are now the standard of care.
Afshin Ebrahimpour, Manisha Ahir, Min Wang, Anil G. Jegga, Mark D. Bonnen, N. Tony Eissa, Sydney B. Montesi, Ganesh Raghu, Yohannes T. Ghebre   +8 more
doaj   +1 more source

Engineering an artificial trachea: Quantitative benchmarks and modular strategies for mechanics, epithelialization, and vascular integration

FlexMat, EarlyView.
In this work, we first examine the limitations of surgical repair and stenting, including migration, granulation, mucus plugging, and infection. We then translate these failures into engineering constraints involving geometry, mechanics, fixation, degradation, junctional stress, and remodeling.
Yiwei Xu, Hanqing Dai, Qianwang Ye, Wanlu Zhang, Na Wang, Lei Xiong, Ruiqian Guo   +6 more
wiley   +1 more source

Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy

iNew Medicine, EarlyView.
Therapeutic mechanism, clinical efficacy and future directions for nerandomilast in pulmonary fibrosis. ABSTRACT The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP),
Qianwen Bai, Jia Deng, Hongquan Wang, Yao Yao, Tao Wang   +4 more
wiley   +1 more source

Andrographolide Modulates Fibrogenic and Oxidative Stress Responses in Human Lung Fibroblasts

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Pulmonary fibrosis is a progressive lung disorder characterized by fibroblast activation and excessive extracellular matrix deposition. Andrographolide (ANDRO) has been reported to attenuate pulmonary fibrosis, but the underlying molecular mechanisms remain incompletely understood.
Yu‐Hsin Tseng, Yen‐Hsien Wu, Yi‐Ching Liu, I‐Chen Chen, Chung‐Yu Yeh, Shang‐En Huang, Ren‐Long Jan, Jwu‐Lai Yeh, Jong‐Hau Hsu   +8 more
wiley   +1 more source